Cantargia AB (publ) (CANTA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Kantargia Q2 Report 2025 presentation. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to the speakers. CEO Damian Marin, CFO Patrik Renvlad, and CBO Tan Burkian, please go ahead. Hello, everybody, and welcome to this presentation today of our 2Q and first half interim report 2025. Moving straight on, we have our safe harbor statement. We are, of course, a listed company on NASDAQ Stockholm Exchange. And as has just been mentioned, you have three speakers here today, myself, interim CEO, Tom McKean, our Chief Business Officer, and Patrick Remblad, our Chief Financial Officer. So moving to the events of the second quarter and the events since the end of that period as well. In the second quarter, we appointed Morton Lind Jensen as our Chief Medical Officer. We then moved on to select Treatment-resistant atopic dermatitis is the second indication for our CAN10 phase 2 program, CAN10 being our anti-IL-1 antibody for immune inflammatory disorders. We also announced that the pharmacokinetic modeling of CAN10 confirmed the choice of every four-week dosing in phase 2, coming from our first in-human study that has been running for some time and is now nearing its end. Also importantly, during the quarter, the US FDA awarded to Naginolimab, our most advanced product in oncology, a fast track designation for the treatment of patients expressing high levels of IL-1 RAP in combination with chemotherapy to treat patients with PDAC, pancreatic ductal adenocarcinoma. Finally, we signed a loan facility of 50 million Swedish krone that to provide us with extra flexibility as we held deal discussions, which I'm sure everybody now knows about. And in fac...